Your browser doesn't support javascript.
loading
Histopathological response to chemotherapy and survival of mucinous type gastric cancer.
Caspers, Irene A; Slagter, Astrid E; Vissers, Pauline A J; Lopez-Yurda, Martha; Beerepoot, Laurens V; Ruurda, Jelle P; Nieuwenhuijzen, Grard A P; Gisbertz, Suzanne S; Van Berge Henegouwen, Mark I; Hartgrink, Henk H; Goudkade, Danny; Kodach, Liudmila L; Van Sandick, Johanna W; Verheij, Marcel; Verhoeven, Rob H A; Cats, Annemieke; Van Grieken, Nicole C T.
Afiliación
  • Caspers IA; Department of Gastrointestinal Oncology, Netherlands Cancer Institute, Antoni van Leeuwenhoek, Amsterdam, The Netherlands.
  • Slagter AE; Department of Pathology, Amsterdam University Medical Center, Cancer Center Amsterdam, Amsterdam, the Netherlands.
  • Vissers PAJ; Department of Radiation Oncology, Netherlands Cancer Institute, Antoni van Leeuwenhoek, Amsterdam, The Netherlands.
  • Lopez-Yurda M; Department of Research & Development, Netherlands Comprehensive Cancer Organization (IKNL), Utrecht, the Netherlands.
  • Beerepoot LV; Department of surgery, Radboud University Medical center, Nijmegen, the Netherlands.
  • Ruurda JP; Department of Biometrics, Netherlands Cancer Institute, Antoni van Leeuwenhoek, Amsterdam, The Netherlands.
  • Nieuwenhuijzen GAP; Department of Oncology, Elisabeth Two Cities Hospital, Tilburg, the Netherlands.
  • Gisbertz SS; Department of Surgical Oncology, University Medical Center Utrecht, Utrecht, the Netherlands.
  • Van Berge Henegouwen MI; Department of Surgery, Catharina Hospital, Eindhoven, the Netherlands.
  • Hartgrink HH; Department of Surgery, Amsterdam University Medical Center location University of Amsterdam, Amsterdam, the Netherlands.
  • Goudkade D; Cancer Treatment and Quality of Life, Cancer Center Amsterdam, Amsterdam, The Netherlands.
  • Kodach LL; Department of Surgery, Amsterdam University Medical Center location University of Amsterdam, Amsterdam, the Netherlands.
  • Van Sandick JW; Cancer Treatment and Quality of Life, Cancer Center Amsterdam, Amsterdam, The Netherlands.
  • Verheij M; Department of Surgical Oncology, Leiden University Medical Center, Leiden, The Netherlands.
  • Verhoeven RHA; Department of Pathology, Zuyderland Medical Center, Sittard-Geleen, the Netherlands.
  • Cats A; Department of Pathology, Netherlands Cancer Institute, Antoni van Leeuwenhoek, Amsterdam, The Netherlands.
  • Van Grieken NCT; Department of Surgical Oncology, Netherlands Cancer Institute, Antoni van Leeuwenhoek, Amsterdam, The Netherlands.
J Natl Cancer Inst ; 2024 Sep 14.
Article en En | MEDLINE | ID: mdl-39276158
ABSTRACT

BACKGROUND:

Data on the clinicopathological characteristics of mucinous gastric cancer (muc-GC) are limited. This study compares the clinical outcome and response to chemotherapy between patients with resectable muc-GC, intestinal (int-GC) and diffuse (dif-GC) gastric cancer.

METHODS:

Patients from the D1/D2 study or the CRITICS trial were included in exploratory surgery-alone (SAtest) or chemotherapy test (CTtest) cohorts. Real-world data from the Netherlands Cancer Registry on patients treated between with surgery-alone (SAvalidation), and receiving preoperative chemotherapy with or without postoperative treatment (CTvalidation) were used for validation. Histopathological subtypes were extracted from pathology reports filed in the Dutch Pathology Registry and correlated with tumor regression grade (TRG) and relative survival (RS).

RESULTS:

In SAtest (n = 549) and SAvalidation (n = 8062) cohorts, muc-GC patients had a five-year RS of 39% and 31%, similar to or slightly better than dif-GC (43% and 29%, p = .52 and p = .011), but worse than int-GC (55% and 42%, p = .11 and p < .001). In CTtest (n = 651) and CTvalidation (n = 2889) cohorts, muc-GC showed favorable TRG (38% and 44% (near-)complete response) compared to int-GC (26% and 35%) and dif-GC (10% and 28%, p < .001 and p = .005). The 5-year RS in CTtest and CTvalidation cohorts for muc-GC (53% and 48%) and int-GC (58% and 59%) was significantly better compared to dif-GC (35% and 38%, p = .004 and p < .001).

CONCLUSION:

Recognizing and incorporating muc-GC into treatment decision-making of resectable GC can lead to more personalized and effective approaches, given its favorable response to preoperative chemotherapy in relation to int-GC and dif-GC and its favorable prognostic outcomes in relation to dif-GC.
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Idioma: En Revista: J Natl Cancer Inst Año: 2024 Tipo del documento: Article País de afiliación: Países Bajos Pais de publicación: Estados Unidos
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Idioma: En Revista: J Natl Cancer Inst Año: 2024 Tipo del documento: Article País de afiliación: Países Bajos Pais de publicación: Estados Unidos